Objectives: To compare the effectiveness and safety of self-expandable, sirolimus-eluting Stentys stents (SES) and second-generation drug-eluting stents (DES-II) for the treatment of the unprotected left main (ULM).
| INTRODUCTION
Critical stenosis of the unprotected left main (ULM) have a detrimental impact on short and long term survival. or of stent oversizing in the side branch, with a potential risk of dissection or even perforation. 8, 9 The self-expandable Stentys ® stent represents a potential solution for these issues. This nitinol (nickel and titanium alloy) sirolimuseluting (in his latest versions) stent exerts, upon deployment, a constant outward force, which allows it to correctly appose against the vessel wall even in case of sudden caliber changes. This device has been tested in various settings, from ST-elevation myocardial infarction (STEMI) to everyday clinical practice with good demonstration of safety and efficacy. [10] [11] [12] Few studies have to date evaluated the safety and effectiveness of self-expandable Stentys stents in the treatment of ULM stenosis. 13, 14 Moreover, few data are available regarding the sirolimuseluting version of these self-expandable devices, whereas no comparisons with second-generation DES have been performed in the setting of ULM. Consequently, we conducted the present study to compare sirolimus-eluting Stentys stents (SES) and second-generation DES in the treatment of the ULM.
| METHODS
The Safety and effectiveness of the self-aPposing, bAlloon-delivered, Given the longer follow-up of the patients included in the FAILS2 study, only events occurring in the first 250 days (the median value of follow-up of the SPARTA) were included, while the others were censored.
Multiple imputations were used to address missing data (http:// www.jstatsoft.org/v45/i07/). Due to lack of randomization regards the choice of the stent for the ULM, a propensity score (PS) was gen- were considered to indicate statistical significance.
| RESULTS
One hundred and fifty one patients were treated for ULM lesions with SES (out of 278 patients included in the SPARTA registry) and 1270 from the FAILS-2 registry with second-generation DES (Figure 1 ).
Baseline features before propensity score are reported in Supporting Information Table 3 ).
After propensity score with matching ( Figure 1 ), 129 patients treated with SES and 258 with second-generation DES were included.
Distribution of propensity score pre-matching and post-matching is shown in Supporting Information Figures 1 and 2 .
Baseline features were balanced, with a prevalence of women of 33% in both groups (Tables 1 and 2 In the subgroup of patients treated with a 2-stent strategy for the ULM bifurcation, rates of MACE did not differ between SES and second-generation DES (7.0% vs. 5.9%, P = 0.21), as well as those of TLR on ULM (4.5% vs. 3.9%, P = 0.90, Figure 4) . Similarly, for ULM bifurcations treated with a provisional approach, the rate of MACE was 10.1% in both groups, without differences in TLR on ULM (0.9% vs. 2.9%, P = 0.26, Figure 5 ).
| DISCUSSION
The main result of the present large, propensity-matched registry is that self-apposing SES can be potentially adopted in the treatment of SES present a dedicated release system, different from the balloondelivery systems of currently available DES. Of note, in the present study we included both the first generation of SES with the traditional Stentys release system and the more recent balloon-delivered Xposition Stentys. to be confirmed in a prospective setting, as only randomized clinical trials are the only type of evidence allowing inferential aims. Finally, the limited follow-up duration might prevent to observe differences between these different kinds of stents in terms of TLR, which may occur in a later phase following the procedure.
| CONCLUSIONS
The self-expandable, SES may be safely and effectively adopted to treat ULM lesions, as they reported comparable rates of adverse cardiovascular events at follow-up as compared to second-generation DES. The Stentys stents may provide a valuable option for the treatment of ULM stenosis in clinical practice, when the anatomical features of the ULM may require a stent able to adapt to marked caliber changes.
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